The IgG1/G2 subclass shift - a sensitive, tissue nonspecific marker for malignancy. Diagnostic performance with squamous cell carcinoma of the head and neck

被引:9
作者
Anderhuber, W
Steinschifter, W
Schauenstein, E
Gotschuli, A
Habermann, W
Fischer, M
Felsner, P
Schauenstein, K
机构
[1] Graz Univ, Dept Biochem, A-8010 Graz, Austria
[2] Graz Univ, Dept Otolaryngol, A-8010 Graz, Austria
[3] Graz Univ, Dept Gen & Expt Pathol, A-8010 Graz, Austria
关键词
squamous cell carcinoma; head-neck region tumours; tumour marker; IgG subclasses;
D O I
10.1038/sj.bjc.6690283
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A significant decrease in %IgG1 accompanied by an increase in %IgG2 in total serum IgG has been previously reported as a highly sensitive marker for detecting early stages of carcinomas of various localizations. Here we investigated the question as to whether this phenomenon is also observed in sera of patients with squamous cell carcinoma of the head-neck region (SCC-HN), and to evaluate its diagnostic performance in the post-operative monitoring. Using quantitative affinity chromatography, serum concentrations of IgG1, IgG2 and total IgG were determined in 81 patients with different stages of primary and untreated SCC-HN, in 51 SGG-HN patients in post-therapeutical follow up, and in 33 patients with organ matched benign diseases. The data were compared with a total of 174 healthy controls. It was found that (i) 105 SCC-HN patients exhibited a mean value of 56.0 +/- 0.7% IgG1, which likewise differed from healthy controls (63.2 +/- 0.5) and benign diseases (61.5 +/- 1.0) with P < 0.0005, (ii) sensitivities and specificities for discriminating primary malignancies from healthy controls were 70 and 74% respectively, and from benign diseases 65 and 76%, (iii) highest sensitivities and specificities were observed with posttherapeutic cases suffering from tumour recurrence (88% and 75%) or patients with distant metastases (87% and 86%), (iv) apparently tumour-free post-therapeutic patients showed a mean %IgG1 not different from the normal value. The decrease in %IgG1 accompanied by increased %IgG2 is an efficient, sensitive and early marker of SCC-HN, which appears particularly useful for the post-therapeutic monitoring.
引用
收藏
页码:1777 / 1781
页数:5
相关论文
共 21 条
[1]   SQUAMOUS-CELL CARCINOMA ANTIGEN - PRESENT CLINICAL RELEVANCE OF A NEW TUMOR-MARKER IN PATIENTS WITH HEAD AND NECK-CANCER - PRELIMINARY-RESULTS OF A PROSPECTIVE-STUDY AFTER 12 MONTHS [J].
CLASEN, B ;
ROETTGER, D ;
SENEKOWITSCH, R ;
MENZ, E .
LARYNGOLOGIE RHINOLOGIE OTOLOGIE VEREINIGT MIT MONATSSCHRIFT FUR OHRENHEILKUNDE, 1988, 67 (08) :420-425
[2]  
DREYFUSS AI, 1992, CANCER-AM CANCER SOC, V70, P2499, DOI 10.1002/1097-0142(19921115)70:10<2499::AID-CNCR2820701018>3.0.CO
[3]  
2-#
[4]  
EIBLING DE, 1989, LARYNGOSCOPE, V99, P117
[5]  
FISCHBACH W, 1990, CANCER, V65, P1321, DOI 10.1002/1097-0142(19900315)65:6<1321::AID-CNCR2820650612>3.0.CO
[6]  
2-Y
[7]   Plasma platelet-derived growth factor: Preliminary study of a potential marker in head and neck cancer [J].
Gleich, LL ;
Srivastava, L ;
Gluckman, JL .
ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 1996, 105 (09) :710-712
[8]  
KAWANO Y, 1994, J IMMUNOL, V153, P4948
[9]  
KOCH T, 1989, HNO, V37, P454
[10]  
KRONBERGER L, 1994, 2ND EUROPEAN CONGRESS ON SENOLOGY, P479